# THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease

> **NCT01355120** · PHASE2 · COMPLETED · sponsor: **Prof. Dr. med. Dirk Schadendorf** · enrollment: 171 (actual)

## Conditions studied

- Ocular Melanoma

## Interventions

- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT01355120
- **Lead sponsor:** Prof. Dr. med. Dirk Schadendorf
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2012-09
- **Final completion:** 2013-09
- **Target enrollment:** 171 (ACTUAL)
- **Last updated:** 2025-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01355120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01355120, "THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01355120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*